ABSTRACT
OBJECTIVE: Cathepsin K plays essential roles in bone resorption and is intensely investigated as a therapeutic target for the treatment of osteoporosis. Hence an assessment of the active form of cathepsin K may provide important biological information in metabolic bone diseases, such as osteoporosis or ankylosing spondylitis. METHODS: Presently there are no robust assays for the assessment of active cathepsin K in serum, and therefore an ELISA specifically detecting the N-terminal of the active form of cathepsin K was developed. RESULTS: The assay was technically robust, with a lowest limit of detection (LOD) of 0.085 ng/mL. The average intra- and inter-assay CV% were 6.60% and 8.56% respectively. The dilution recovery and spike recovery tests in human serum were within 100±20% within the range of the assay. A comparison of latent and active cathepsin K confirmed specificity towards the active form. Quantification of the levels of active cathepsin K in supernatants of purified human osteoclasts compared to corresponding macrophages showed a 30-fold induction (p<0.001). In contrast, in serum samples from osteoporotic women on estrogen or bisphosphonate therapy and from ankylosing spondylitis patients no clinically relevant differences were observed. CONCLUSION: In summary, we have developed a robust and sensitive assay specifically detecting the active form of cathepsin K; however, while it monitors osteoclasts with high specificity in vitro, it appears that circulating levels of active cathepsin K do not reflect bone changes under these circumstances.
Subject(s)
Cathepsin K/blood , Enzyme-Linked Immunosorbent Assay/methods , Osteoclasts/enzymology , Osteoporosis/blood , Spondylitis, Ankylosing/blood , Animals , Antibodies, Monoclonal/chemistry , Bone Density Conservation Agents/therapeutic use , Bone and Bones/enzymology , Bone and Bones/pathology , Diphosphonates/therapeutic use , Enzyme Activation , Female , Humans , Macrophages/cytology , Macrophages/enzymology , Mice , Middle Aged , Osteoclasts/cytology , Osteoporosis/drug therapy , Osteoporosis/enzymology , Osteoporosis/pathology , Sensitivity and Specificity , Spondylitis, Ankylosing/enzymology , Spondylitis, Ankylosing/pathologyABSTRACT
Drug development for dementias is significantly hampered by the lack of easily accessible biomarkers. Fluid biomarkers of dementias provide indications of disease stage, but have little prognostic value, cannot detect early pathological changes, and can only be measured in CSF (cerebrospinal fluid) which significantly limits their applicability. In contrast, imaging based biomarkers can provide indications of probability of disease progression, yet are limited in applicability due to cost, radiation and radio-tracers. These aspects highlight the need for other approaches to the development of biomarkers of dementia, which should focus on not only providing information about pathological changes, but also on being measured easily and reproducibly. For other diseases, focus on development of assays monitoring highly specific protease-generated cleavage fragments of proteins has provided assays, which in serum or plasma have the ability to predict early pathological changes. Proteolytic processing of brain proteins, such as tau, APP, and α-synuclein, is a key pathological event in dementias. Here, we speculate that aiming biomarker development for dementias at detecting small brain protein degradation fragments of generated by brain-derived proteases specifically in blood samples could lead to the development of novel markers of disease progression, stage and importantly of treatment efficacy.
ABSTRACT
Osteopetrosis is the result of mutations affecting osteoclast function. Careful analyses of osteopetrosis have provided instrumental information on bone remodeling, including the coupling of bone formation to bone resorption. Based on a range of novel genetic mutations and the resulting osteoclast phenotypes, we discuss how osteopetrosis models have clarified the function of the coupling of bone formation to bone resorption, and the pivotal role of the osteoclast and their function in this phenomenon. We highlight the distinct possibility that osteoclast activities can be divided into two separate avenues: bone resorption and control of bone formation.
Subject(s)
Mutation , Osteoclasts/physiology , Osteopetrosis/genetics , Adaptor Proteins, Signal Transducing/deficiency , Adaptor Proteins, Signal Transducing/genetics , Animals , Autophagy-Related Proteins , Bone Remodeling/genetics , Bone Remodeling/physiology , Bone Resorption/genetics , Bone Resorption/physiopathology , Carbonic Anhydrase II/deficiency , Carbonic Anhydrase II/genetics , Cathepsin K , Cathepsins/genetics , Chloride Channels/genetics , Disease Models, Animal , Humans , Membrane Glycoproteins/deficiency , Membrane Glycoproteins/genetics , Membrane Proteins/genetics , Mice , Models, Biological , Osteoblasts/pathology , Osteoblasts/physiology , Osteoclasts/pathology , Osteopetrosis/etiology , Osteopetrosis/pathology , Osteopetrosis/physiopathology , RANK Ligand/deficiency , RANK Ligand/genetics , Receptor Activator of Nuclear Factor-kappa B/deficiency , Receptor Activator of Nuclear Factor-kappa B/genetics , Ubiquitin-Protein Ligases/genetics , Vacuolar Proton-Translocating ATPases/geneticsABSTRACT
Although several treatments for osteoporosis exist, further understanding of the mode of action of current treatments, as well as development of novel treatments, are of interest. Thus, preclinical models of osteoporosis are very useful, as they provide the possibility for gaining knowledge about the cellular mechanisms underlying the disease and for studying pharmaceutical prevention or intervention of the disease in simple and strictly controlled systems. In this review, we present a comprehensive collection of studies using biochemical markers of bone turnover for investigation of preclinical models of osteoporosis. These range from pure and simple in vitro systems, such as osteoclast cultures, to ex vivo models, such as cultures of embryonic murine tibiae and, finally, to in vivo models, such as ovariectomy and orchidectomy of rats. We discuss the relevance of the markers in the individual models, and compare their responses to those observed using 'golden standard' methods.
Subject(s)
Biomarkers/analysis , Bone and Bones/drug effects , Drug Evaluation, Preclinical , Osteoporosis/drug therapy , Animals , Bone and Bones/metabolism , Disease Models, Animal , Humans , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteoclasts/drug effects , Osteoclasts/metabolism , Osteogenesis/drug effects , Osteoporosis/metabolismABSTRACT
UNLABELLED: We investigated whether the age of the bones endogenously exerts control over the bone resorption ability of the osteoclasts, and found that osteoclasts preferentially develop and resorb bone on aged bone. These findings indicate that the bone matrix itself plays a role in targeted remodeling of aged bones. INTRODUCTION: Osteoclasts resorb aging bone in order to repair damage and maintain the quality of bone. The mechanism behind the targeting of aged bone for remodeling is not clear. We investigated whether bones endogenously possess the ability to control osteoclastic resorption. METHODS: To biochemically distinguish aged and young bones; we measured the ratio between the age-isomerized betaCTX fragment and the non-isomerized alphaCTX fragment. By measurement of TRACP activity, CTX release, number of TRACP positive cells and pit area/pit number, we evaluated osteoclastogenesis as well as osteoclast resorption on aged and young bones. RESULTS: We found that the alphaCTX/betaCTX ratio is 3:1 in young compared to aged bones, and we found that both alpha and betaCTX are released by osteoclasts during resorption. Osteoclastogenesis was augmented on aged compared to young bones, and the difference was enhanced under low serum conditions. We found that mature osteoclasts resorb more on aged than on young bone, despite unchanged adhesion and morphology. CONCLUSIONS: These data indicate that the age of the bone plays an important role in controlling osteoclast-mediated resorption, with significantly higher levels of osteoclast differentiation and resorption on aged bones when compared to young bones.
Subject(s)
Aging/physiology , Bone Remodeling/physiology , Bone and Bones/cytology , Osteoclasts/physiology , Acid Phosphatase/metabolism , Aging/pathology , Animals , Bone Resorption/physiopathology , Bone and Bones/chemistry , Bone and Bones/physiology , Cattle , Cell Adhesion/physiology , Cell Differentiation/physiology , Cells, Cultured , Collagen Type I/analysis , Humans , Isoenzymes/metabolism , Osteoclasts/cytology , Tartrate-Resistant Acid PhosphataseABSTRACT
Estrogen deficiency arising with the menopause promotes marked acceleration of bone resorption, which can be restored by hormone replacement therapy. The inhibitory effects of estrogen seem to involve indirect cytokine- mediated effects via supporting bone marrow cells, but direct estrogen-receptor mediated effects on the bone-resorbing osteoclasts have also been proposed. Little information is available on whether estrogens modulate human osteoclastogenesis or merely inhibit the functional activity of osteoclasts. To clarify whether estrogens directly modulate osteoclastic activities human CD14+ monocytes were cultured in the presence of M-CSF and RANKL to induce osteoclast differentiation. Addition of 0.1-10 nM 17beta-estradiol to differentiating osteoclasts resulted in a dose-dependent reduction in tartrate resistant acid phosphatase (TRACP) activity reaching 60% at 0.1 nM. In addition, 17beta-estradiol inhibited bone resorption, as measured by the release of the C-terminal crosslinked telopeptide (CTX), by 60% at 0.1 nM, but had no effect on the overall cell viability. In contrast to the results obtained with differentiating osteoclasts, addition of 17beta-estradiol (0.001-10 nM) to mature osteoclasts did not affect bone resorption or TRACP activity. We investigated expression of the estrogen receptors, using immunocytochemistry and Western blotting. We found that ER-alpha is expressed in osteoclast precursors, whereas ER- beta is expressed at all stages, indicating that the inhibitory effect of estrogen on osteoclastogenesis is mediated by ER-alpha for the major part. In conclusion, these results suggest that the in vivo effects of estrogen are mediated by reduction of osteoclastogenesis rather than direct inhibition of the resorptive activity of mature osteoclasts.
Subject(s)
Bone Resorption , Estradiol/pharmacology , Osteoclasts/drug effects , Blotting, Western , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/metabolism , Humans , Immunohistochemistry , Osteoclasts/cytology , Osteoclasts/metabolismABSTRACT
Chloride ions play a major role in osteoclast biology and bone homeostasis. In addition to its general cellular roles, chloride is involved in the specific bone resorption activity of osteoclasts. The chloride channel ClC-7 has been shown to be mandatory for bone resorption. It is necessary for the acidification of the resorption lacunae. In addition to ClC-7, other chloride channels and exchangers have been identified in osteoclasts. The bicarbonate-chloride exchanger at the plasma membrane of osteoclasts is important for regulating the cytoplasmic pH during bone resorption. The role of the additional chloride channels or putative chloride channels identified in osteoclasts, volume-regulated anion channel, Chlor.62 and CLIC1 has not been established. To date, ClC-7 is the only known chloride channel whose disruption or mutation leads to a bone disease: osteopetrosis, which is characterized by an increased bone mass. Inhibition of ClC-7 constitutes a new potential way to treat osteoporosis. The expression of ClC-7 is restricted to few tissues with very high expression in the osteoclasts in bone. Pharmacologically, inhibitors of acidification of the resorption lacunae have proved to be unique, as inhibition leads to a decrease in bone resorption without affecting bone formation, suggesting that the coupling principle has been challenged. Thus, ClC-7 inhibitors may prove to be potent for prevention and treatment of osteoporosis.